Focusing on Amgen, analysts at Credit Suisse describe the situation more succinctly – "does the company want to be a game keeper or poacher?" Via its collaboration with Actavis, Amgen's commitment to biosimilars is clear. Indeed, when the generics manufacturer announced its Q4 results last month it revealed that three of the biosimilar products being developed as part of the collaboration are versions of the cancer treatments Avastin, Herceptin and Rituxan – all of which are manufactured by Roche. The game keeper/poacher analogy is not only relevant to Amgen of course, but also the numerous Big Pharma players that are developing both biosimilars and branded biologics. On its recent Q4 conference call with analysts Pfizer confirmed the likely progression of its own Herceptin biosimilar program into Phase III clinical trials later this year. It is also clear to see why the GPA is concerned.